• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

ABBV STOCK HITS RECORD ALL TIME HIGH

Quote
anonymous said:
That would be wonderful, but you betttter find a new broker. Impossible feat. I'd settle for $115 by Q3 and be damn happy. Maybe I'll buy CP if they want to sell site. I'd offer couple mill cash deal and rid this site of the liars and posers.
Click to expand...


U r one big pessimist. I believe my broker, she has never let me down !
 












All-time high of $101.11. Stock is running up ahead of 4th quarter numbers. 4th quarter looks very strong. Stock will be $110 by February. Some analysts are predicting $140-$150 by years end. It's going to be a very exciting year for our company.
 




anonymous said:
All-time high of $101.11. Stock is running up ahead of 4th quarter numbers. 4th quarter looks very strong. Stock will be $110 by February. Some analysts are predicting $140-$150 by years end. It's going to be a very exciting year for our company.
Click to expand...


Broker told me it will likely spit after next annual stockholder meeting. Equivalent valuation will be $250/share by end of year ! ! ! so lets get it now at the bargain price !!.
 




anonymous said:
Broker told me it will likely spit after next annual stockholder meeting. Equivalent valuation will be $250/share by end of year ! ! ! so lets get it now at the bargain price !!.
Click to expand...
$250 per share gives it a higher market cap than J&J's present MC. Highly unlikely unless they bring in another revenue generator that can eventually put up Humira type numbers.
 












Not so fast genuises ! A few more adverse events or ANY negative results in trials of Rova-T, Elagoix, Upadacitinib, or Risankizumab combined with the clock ticking down on Humira could push this stock back to the $60s so fast your head will spin. Let's hope not, but smart investors won't EVER rule it out.
 




anonymous said:
$250 per share gives it a higher market cap than J&J's present MC. Highly unlikely unless they bring in another revenue generator that can eventually put up Humira type numbers.
Click to expand...

Thank you. You finally got it. It took a while I was curious how long it would take here. Hint (can say no more): revenue generator = a blockbuster in the pipeline !!!
 








anonymous said:
No broker in the world would project $250. How TF can anybody with half a brain even respond to this freakin fairy tale ? Hilliarious, but Sad !
Click to expand...
anonymous said:
Not so fast genuises ! A few more adverse events or ANY negative results in trials of Rova-T, Elagoix, Upadacitinib, or Risankizumab combined with the clock ticking down on Humira could push this stock back to the $60s so fast your head will spin. Let's hope not, but smart investors won't EVER rule it out.
Click to expand...
 




AS predicted Abbvie stock will hit $110 by Friday. 4th quarter/year end numbers are very strong. Amgen deal seals our growth for the next 5 years. Rumor is stock will split after Friday. Hold on for a great week
 




I just made 400K HOW SWEET IT IS !!!!!!!!!!!!!!!!!!!!!!!!!!!
ABBVIE INC
NYSE: ABBV
US Markets Open

118.08
▲
+$9.71
+8.96%
January 26, 2018 11:40 AM EST. BATS BZX Real-Time Last Price. Currency In USD
 




Besides Humira's huge gain, Imbruvica popped $708M, almost a 39% gain, well exceeding the $1 million projection by the street. In HVC Haas and lootsie has Viekira and Mavyret revenues UP 63% beating consensus by a YUGE 89%!!! Lower tax rate also boosted 2018 guidance. Adjusted income of $7.33-$7.43 per share, up from $6.45-$6.55 and topping the consensus for $6.57. Expect sales of $32 billion, which will beat street projected $31.4 billion.
 
























Top Bottom
Back
Quote